首页|亚低温疗法联合依达拉奉对sTBI后迟发性低灌注的积极意义分析

亚低温疗法联合依达拉奉对sTBI后迟发性低灌注的积极意义分析

扫码查看
目的:探讨亚低温疗法联合依达拉奉治疗重型颅脑损伤(Severe traumatic brain injury,sTBI)患者的效果及对迟发性低灌注的影响.方法:选取 2021 年 5 月至 2023 年 5 月期间本院收治sTBI患者 82 例,采用双盲法随机分为两组(n=41),对照组患者采用依达拉奉30 mg静脉滴注治疗;观察组患者采用依达拉奉联合亚低温治疗.持续治疗2 w后,分别采用美国国立卫生研究院卒中量表(NIH Stroke Scale,NIHSS)评价神经功能、简易智力状态检查量表(Mini-Mental State Examination,MMSE)评估认知功能,同时以酶联免疫吸附试验检测血清学指标以及以激光多普勒脑血流仪监测脑血流参数,并统计并发症情况.结果:与治疗前相比两组MMSE均升高、NIHSS均降低(P<0.05),其中观察组更显著(P<0.05).与治疗前相比两组血清缺血修饰蛋白(Ischemia modified albumin,IMA)、E神经元特异性烯醇化酶(Neuron-specific enolase,NSE)均降低(P<0.05),其中观察组更显著(P<0.05).与治疗前相比两组脑血流脉搏波速(Pulse wave velocity,Wv)、动态阻力(Dynamic Resistance,DR)均降低,脑部平均血流量(Qmean)、脑部平均血流速度(Vmean)均升高(P<0.05),其中观察组更显著(P<0.05).统计两组并发症情况,对照组vs观察组(7.32%vs 14.63%)(P>0.05).结论:对于sTBI患者使用依达拉奉治疗联合亚低温疗法,能改善患者的认知功能和神经功能,改善患者脑血流水平,预防迟发性低灌注的发生.
Analysis of positive significance of mild hypothermia therapy combined with Edaravone in delayed hypoperfusion after sTBI
Objective:To investigate the effect of mild hypothermia therapy combined with edaravone on patients with severe traumatic brain injury(sTBI)and its impact on delayed hypoperfusion.Methods:A total of 82 patients with sTBI admitted to our hospital from May 2021 to May 2023 were selected and randomly divided into two groups using a double-blind method(n=41).The control group patients were treated with edaravone 30 mg intravenously,while the observation group patients were treated with edaravone combined with mild hypothermia.After 2 weeks of continuous treatment,the National Institutes of Health Stroke Scale(NIHSS)was used to evaluate neurological function,the Mini-Mental State Examination(MMSE)was used to evaluate cognitive function,and the enzyme-linked immunosorbent assay was used to detect serum indicators.The laser Doppler cerebral blood flow meter was used to monitor cerebral blood flow parameters,and the complications were statistically analyzed.Results:Compared with before treatment,both groups showed increased MMSE scores and decreased NIHSS scores(P<0.05),with more significant improvement in the observation group(P<0.05).Compared with before treatment,both groups showed decreased serum ischemia modified albumin(IMA)and neuron-specific enolase(NSE)levels(P<0.05),with more significant improvement in the observation group(P<0.05).Compared with before treatment,both groups showed decreased pulse wave velocity(Wv)and dynamic resistance(DR),as well as increased mean cerebral blood flow(Qmean)and mean cerebral blood flow velocity(Vmean)(P<0.05),with more significant improvement in the observation group(P<0.05).The statistics of the complications in the two groups showed that the control group vs the observation group(7.32%vs 14.63%)(P>0.05).Conclusion:The use of edaravone combined with mild hypothermia therapy for sTBI patients can improve patients'cognitive function and neurological function,improve their cerebral blood flow level,and prevent the occurrence of delayed hypoperfusion.

Delayed hypoperfusionSevere craniocerebral injuryMild low temperatureEdaravone

王婷婷、王琳琳、张小曼

展开 >

河南大学第一附属医院神经内科,河南 开封 475000

迟发性低灌注 重型颅脑损伤 亚低温 依达拉奉

河南省医学教育研究项目2023年度开封市科技发展计划项目

Wjlx20204452303020

2024

四川生理科学杂志
四川省生理科学会

四川生理科学杂志

影响因子:0.575
ISSN:1671-3885
年,卷(期):2024.46(8)